Icon

KOSELUGO (nda213756)- (EQ 10MG BASE,EQ 25MG BASE)

SELUMETINIB SULFATE ASTRAZENECA
EQ 10MG BASE,EQ 25MG BASE
No No
2029-Mar-26 2025-Apr-10
None None
None No
KOSELUGO is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
0 0 0
Total Other Developers 2
Drugs with Suitability No
EQ 10MG BASE ** ** - - -
EQ 25MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.